Immuneering has entered into an agreement to expand its existing relationship with Bristol-Myers Squibb (BMS) for the use of Immuneering's proprietary computational biology methods to identify biological insights that would help in the discovery and development of medicines.
Novartis has acquired CoStim Pharmaceuticals, an immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.